Objective-Recombinant streptococcal serum opacity factor (rSOF) mediates the in vitro disassembly of human plasma high-density lipoprotein (HDL) into lipid-free apolipoprotein (apo) A-I, a neo-HDL that is cholesterol poor, and a cholesteryl ester-rich microemulsion (CERM) containing apoE. Given the occurrence of apoE on the CERM, we tested the hypothesis that rSOF injection into mice would reduce total plasma cholesterol clearance via apoE-dependent hepatic low-density lipoprotein receptors (LDLR). Methods and Results-rSOF (4 g) injection into wild-type C57BL/6J mice formed neo-HDL, CERM, and lipid-free apoA-I, as observed in vitro, and reduced plasma total cholesterol (Ϫ43%, t 1/2 ϭ44Ϯ18 minutes) whereas control saline injections had a negligible effect. Similar experiments with apoE Ϫ/Ϫ and LDLR Ϫ/Ϫ mice reduced plasma total cholesterol Ϸ0% and 20%, respectively. rSOF was potent; injection of 0.18 g of rSOF produced 50% of maximum reduction of plasma cholesterol 3 hours postinjection, corresponding to a Ϸ0.5-mg human dose. Most cholesterol was cleared hepatically (Ͼ99%), with rSOF treatment increasing clearance by 65%. Conclusion-rSOF injection into mice formed a CERM that was cleared via hepatic LDLR that recognize apoE. This reaction could provide an alternative mechanism for reverse cholesterol transport. (Arterioscler Thromb Vasc Biol.
S erum opacity factor (SOF), a virulence determinant produced by the group A streptococcus, Streptococcus pyogenes, is expressed by approximately half of the clinical isolates of S. pyogenes, 1 an important human pathogen that causes pharyngitis, tonsilitis, impetigo, necrotizing fasciitis, and toxic shock syndrome. SOF is a Ϸ110-kDa protein that is found both in culture supernatants and attached to the surface of streptococci via its cell wall-anchoring motif LPASG. The N-terminal two thirds of SOF is composed of alternating variable and conserved regions and contains the fibulin-1 binding domain and a domain that causes plasma to opacify. 2, 3 The carboxyl terminus of SOF is highly conserved and contains a repeating peptide domain that binds to fibronectin 4 and fibrinogen 5 and mediates streptococcal adhesion to host cells. 6 SOF opacifies serum by disrupting high-density lipoprotein (HDL), its exclusive target, 3 and forms a large cholesteryl ester-rich microemulsion (CERM; r Ϸ100 to 200 nm), lipid-free (LF) apolipoprotein (apo) A-I, and small neo-HDL that are cholesterol poor and phospholipid rich. 7 The CERM contains apoE and its heterodimer with apoA-II as its sole proteins 8 and the neutral lipids of Ϸ400,000 HDL particles. 7 SOF is potent and catalytic; within 30 minutes at 37°C, 10 nmol/L recombinant SOF (rSOF) quantitatively converts 4 mol/L HDL to CERM, neo-HDL, and LF apoA-I. 9 Kinetic studies 7, 9 led to a model of rSOF as a heterodivalent fusogen that uses a high-affinity docking site to displace labile apoA-I and bind to exposed cholesteryl ester (CE) on HDL; the rSOF-HDL complex recruits additional HDL with its binding-delipidation site and through multiple fusion steps forms a CERM. On the basis of the high CE and apoE content of the CERM particle, we hypothesized that SOF would increase reverse cholesterol transport (RCT) by targeting the CERM to multiple apoE-dependent hepatic receptors. 7, 8 Treating plasma with rSOF makes it a better acceptor of macrophage cholesterol efflux and a better lecithin:cholesterol acyltransferase substrate, 10 and targets the CERM to cellular uptake via low-density lipoprotein receptor (LDLR), the heparin sulfate proteoglycan receptor (Syndecan-1), LDLR-related protein-1, and scavenger receptor class B type 1. 8 However, the effects of SOF on the final RCT step, hepatic uptake, remained to be tested in vivo. Here, we show that intravenous injection of rSOF into mice formed neo-HDL, CERM, and LF apoA-I in vivo and enhanced hepatic clearance of CERM-cholesterol in an apoE-and LDLRdependent way.
Methods Materials
A polyhistidine-tagged, truncated recombinant form of sof2 (rSOF) encoding amino acids 38 to 843 was cloned and expressed in Escherichia coli and purified by metal affinity chromatography as described previously. 4 All mice (wild-type [WT] C57BL/6J, apoE Ϫ/Ϫ , and LDLR Ϫ/Ϫ ) mice were obtained from the Jackson Laboratory. Mice were maintained on normal chow and used at 11 to 12 weeks of age.
Analytic Methods
Unless otherwise indicated, Tris-buffered saline (10 mmol/L Tris, 100 mmol/L NaCL, 1 mmol/L EDTA) was used throughout. Total mouse lipoproteins were isolated by flotation at dϭ1.21 g/mL and separated into subclasses by size exclusion chromatography over Superose HR6 (GE HealthCare) as previously described. 7 Typically, 200 to 500 L of sample was injected, and the effluent was monitored by absorbance at 280 nm and by immunoblot and lipid analysis of collected 1-mL fractions. Because of its large size, the CERM elutes close to the column void volume (Ϸ15 mL). Plasma cholesterol, phospholipid, and triglyceride were determined using kits (Wako Chemicals USA, Richmond, VA). All animal procedures were carried out in accordance with institutional animal care and use committee guidelines.
ApoA-I Analysis
Selected chromatographic fractions were analyzed by SDS-PAGE on 4% to 20% Tris-glycine precast gels (Invitrogen, Carlsbad, CA). Bands were visualized by probing with rabbit anti-mouse apoA-I (Academy Bio-Medical, Houston, TX) and anti-mouse apoE (Abcam, Cambridge, MA). Bands were revealed using SuperSignal West Femto Chemiluminescence Substrate (Thermo-Fisher Scientific, Rockford, IL).
Mouse Plasma Cholesterol Decay Kinetics
Three types of kinetics studies were conducted in mice. In the first experiment, various doses of rSOF or saline were injected via tail vein, At various times following injection, the mice were anesthetized, their chest cavities were opened, and the blood was collected by heart puncture and transferred to wet ice. The plasma was separated from the cells by low-speed centrifugation at 4°C, and the total plasma cholesterol was determined. Each time point represents triplicate mice, and each cholesterol measurement was performed in triplicate. In some experiments, plasma was also assayed for phospholipid and triglyceride.
Mice were also injected with various rSOF doses (nϭ3 mice/ dose), and their plasma was collected after 3 hours, chilled on wet ice, and split into 2 aliquots. One was analyzed for total cholesterol, whereas total plasma lipoproteins were isolated from the other aliquot by flotation at dϭ1.21 g/mL and analyzed by size exclusion chromatography.
In the second experiment, [ 3 H]cholesterol in ethanol (50 L) was added to pooled mouse plasma (Ϸ1.5 mL) and incubated overnight at 37°C, after which analysis of the plasma showed that Ϸ98% of the [ 3 H]cholesterol had been converted to its ester. The plasma was split into 2 equal volumes, treated with rSOF (4 g/mL) or an equal volume of saline, and incubated for 18 hours at 37°C. Mice were injected intravenously via tail vein with saline or rSOF-treated plasma, euthanized, and bled by heart puncture at various times. Plasma was isolated by low-speed centrifugation and ␤-counted, and the percentage of injected radioactivity was calculated.
In the third experiment, [ 3 H]cholesterol was incubated overnight at 37°C as described above and split into 2 aliquots, one that was treated with rSOF (2 g/mL) and another that was treated with an equal volume of saline. Size exclusion chromatography showed that after incubation of whole mouse plasma with [ 3 H]cholesterol overnight at 37°C, [ 3 H]cholesterol transferred from small to large HDL, with the remainder appearing in the low-density lipoprotein (LDL) range (Supplemental Figure IA and IB, available online at http://atvb.ahajournals.org); this interconversion was also reported in the rat. 11 Figure IC) .
The samples (0.35 Ci/50 L) were injected into 2 groups of mice (nϭ3). After 1 hour, the mice were anesthetized and perfused with saline via the aorta, and the liver, spleen, testes, lungs, and kidneys were collected, weighed, lyophilized, and extracted with hexane/ isopropanol(3/2), which was transferred to scintillation vials and the solvent removed by evaporation. Scintillation fluid was added to the vials, which were ␤-counted, and the total organ uptake calculated (cpm). Between 35% and 40% of the radioactivity was recovered in the organs.
Statistical Analysis
All values are expressed as meanϮSD. Data were compared using ANOVA followed by the Student t test for pairwise comparisons against rSOF-treated and saline-treated groups. Values of PϽ0.05 were considered statistically significant. Statistical analysis and calculation of regression curves was performed using SigmaPlot 11.2 (Systat Software, Inc.). Rate constants were calculated from regression fits of the data points versus time.
Results

Effects of rSOF on Plasma Cholesterol
rSOF (4 g) or an equal volume of saline was injected into WT C57BL/6J, apoE Ϫ/Ϫ , and LDLR Ϫ/Ϫ mice, which were euthanized at various times postinjection ( Figure 1 ). Data were fitted to a first-order polynomial except for the cholesterol decay curves for WT and LDLR Ϫ/Ϫ mice injected with rSOF, which were fitted to a 3-parameter exponential decay. Whereas WT mice receiving saline had similar plasma cholesterol levels irrespective of the time postinjection (Figure 1A) , plasma cholesterol decay half-time in WT mice receiving rSOF was t 1/2 ϭ44Ϯ18 minutes (r 2 Ͼ0.94). Plasma total cholesterol was significantly reduced by 30 minutes and remained low, with values at 20 hours reduced by 43%, or 57 mg/dL. We also measured phospholipids and triglycerides. In mice receiving rSOF, plasma phospholipid concentrations were not significantly changed between tϭ0 to 3 hours, but they were reduced 36% (PϽ0.01) at 20 hours. In some but not all experiments, rSOF transiently increased plasma triglyceride concentration, which returned to baseline by 20 hours (Supplemental Table I ). Thus, rSOF injection rapidly reduces plasma total cholesterol without a global decrease in other plasma lipids.
To probe the role of apoE and the LDLR in rSOF reduction of plasma cholesterol, we also tested apoE Ϫ/Ϫ and LDLR Ϫ/Ϫ mice. ApoE Ϫ/Ϫ had elevated plasma total cholesterol at baseline, and plasma cholesterol was not affected by rSOF injection ( Figure 1B .) Response of LDLR Ϫ/Ϫ mice was intermediate between WT and apoE Ϫ/Ϫ mice. rSOF injection effected a 20% to 25% decrease in plasma cholesterol at 1 to 3 hours, with a return to control levels by 20 hours ( Figure 1C ).
Size exclusion chromatographic analysis suggests that in the WT mice, the loss of cholesterol was due to the conversion of HDL cholesterol (HDL-C) to CERM (Figure 2A ). At tϭ0 (no rSOF), the very-low-density lipoprotein (VLDL) peak at an elution volume (EV) of 15.5 mL was nil compared with the peak for plasma protein to which all data were normalized. At 30 minutes, a prominent peak was observed at EVϭ14.9, the EV of CERM in vitro. 7 At 60 and 180 minutes postinjection, the magnitude of the CERM peak had increased and shifted to an EV corresponding to smaller particles. At 1200 minutes, the peak was greatly reduced and had a peak EVϭ15.2, between that of VLDL and that of the largest CERM. Thus, rSOF injection into mice induced formation of CERM, which was cleared from the plasma with a concomitant 43% reduction in plasma cholesterol. Although based on light scattering and not absorption, the reduction in the peak at an EV of Ϸ15 mL suggests that most of the cholesterol remaining in plasma at 1200 minutes was not CERM associated. This was confirmed by cholesterol assays of the plasma profiles from the same WT mice as Figure 1A . At tϭ30, 60, and 180 minutes, 74%, 88%, and 93%, respectively, of the formerly HDL-C was associated with the CERM (Figure 2E to 2H). These data also clearly show a small fraction of cholesterol eluting as a peak with the same EV as that of neo-HDL (EVϭ32 to 34 mL). Finally, at 1200 minutes, the data show that the CERM peak had cleared and the reappearance of a cholesterolpositive peak eluting as HDL. Assays of the same fractions for phospholipid and triglyceride shown in Supplemental Figure II showed that the total cholesterol/phospholipid weight ratio in HDL at tϭ0.60 decreased to 0.12 and 0.08 in neo-HDL at 60 and 180 minutes, respectively, and recovered to 0.32 in HDL at 1200 minutes. These total cholesterol/phospholipid weight ratios for HDL and neo-HDL in vivo are comparable to what we observed in vitro with human HDL: 0.57 for HDL and 0.10 for neo-HDL. 7 The chromatographic profiles of plasma from apoE Ϫ/Ϫ and LDLR Ϫ/Ϫ mice following injection of saline were distinct from those of WT mice, both showing profound CERM accumulation. As expected for both of these models of hyperlipidemia, the magnitude of the absorbance corresponding to VLDL (EVϭ15.5) at tϭ0 minutes was higher than that of WT mice, particularly for the apoE Ϫ/Ϫ mice (Figure 2A to 2B). Following rSOF injection into apoE Ϫ/Ϫ mice, the absorbance due to CERM formation increased with time. Unlike the profiles of WT mice, which showed a shift in the EV toward the void volume at 30 minutes, the CERM that formed in the plasma of apoE Ϫ/Ϫ mice were much smaller, approximately the size of VLDL seen at tϭ0. The CERM peak accumulated with time, and by 1200 minutes, larger particles were observed ( Figure 2B ). LDLR Ϫ/Ϫ chromatographic profiles were similar to those observed for the plasma of WT mice, with peaks corresponding to the CERM in LDLR Ϫ/Ϫ mice shifted into the void volume between 60 and 180 minutes, indicating formation of large CERM ( Figure 2C) . At 180 minutes, the peak was bimodal, with the shoulder seen at 60 minutes appearing as a prominent peak. By 1200 minutes, the CERM peak was partially cleared, only twice that of the VLDL seen at tϭ0.
Effects of rSOF on the Turnover of Plasma [ 3 H]CE
We compared the turnover of plasma [ 3 H]CE with and without rSOF treatment. A 3-parameter exponential fit of our data ( Figure 3A) gave a rate constant, k, of 0.055Ϯ0.02 Figure 1 and are normalized to the maximum absorption peak for plasma proteins. D to H, Chromatographic profile of plasma total cholesterol following rSOF (4 g) injection into WT mice at various times as shown. Left and right vertical dotted lines denote EV for HDL and neo-HDL respectively. Plasma (35 L each) from 3 mice was pooled and diluted to 140 L and injected into the size exclusion column using a 100-L loop. One-milliliter fractions were assayed for total cholesterol. Filled curves in E to G correspond to the profiles for neo-HDL. minutes Ϫ1 (r 2 Ͼ0.94, t 1/2 ϭ18.2Ϯ0.6 minutes Ϫ1 ) for the disappearance of [ 3 H]CE without rSOF treatment and rates that were 1.4 times greater (kϭ0.132Ϯ0.02, r 2 Ͼ0.98, t 1/2 ϭ 7.7Ϯ0.1 minutes) after incubation with rSOF. The respective reductions in plasma radioactivity at 90 minutes were Ϫ58Ϯ5% versus Ϫ91Ϯ3% without and with rSOF incubation. Thus, in mice, rSOF profoundly increased the rate and magnitude of clearance of total plasma cholesterol ( Figure  3B ) and plasma [ 3 H]CE ( Figure 3A ).
rSOF Dosing in Mice
The plasma total cholesterol showed a dose-dependent decrease with increasing dose and a half-maximum decrease at 0.18 g ( Figure 3B ). To analyze the effect of rSOF dose on product formation in vivo, the total plasma lipoprotein from the same mice were analyzed by size exclusion chromatography, which separates VLDL/CERM, HDL, and LF apoA-I ( Figure 4A , I, II, and V, respectively). Under similar conditions, neo-HDL formed in vitro elutes at 32 mL ( Figure 4A , III, arrow). 7 At 1 ng/mouse, the chromatographic profile was only slightly altered relative to that of control mice receiving saline ( Figure 4A ). However, as the dose was increased to 100 ng, peaks I and II were shifted toward earlier and later EV, respectively. These correspond, respectively, to those of a larger CERM and a putative neo-HDL that shifts to a later EV (smaller particle size) with increasing dose (Figure 4A and 4C ). As the dose increased to 10,000 ng, peak I became nearly symmetrical and eluted as an authentic CERM sample, 7 and the peak for neo-HDL decreased to a very low but still detectable level, shown on an expanded scale ( Figure 4D to 4G) . These data, along with the cholesterol chromatographic profiles ( Figure 2D to 2H), show that rSOF generates 2 of its in vitro products, CERM and neo-HDL, in vivo.
rSOF Forms LF ApoA-I In Vivo
No peak for LF apoA-I was observed in Figure 4 because flotation to obtain total plasma lipoprotein sediments unlipidated proteins, which includes LF apoA-I. To establish formation of LF apoA-I in vivo, we collected selected chromatographic fractions of whole plasma from mice at various times following rSOF injection (4 g/mouse) and probed for LF apoA-I by immunoblot analysis. The EV of HDL, neo-HDL, and LF apoA-I formed in vitro are 31.3, 32.4 and 33.9 mL, respectively (Ϯ0.025 mL). 7, 12 Immunoblots of chromatographic fractions of control plasma (no rSOF) show the expected association of apoA-I with HDL (EV 30 and 31 mL) with little and none seen at EV of 34 and 35 mL, respectively, which correspond to LF apoA-I in vitro 7 ( Figure  5B ). In contrast, 1 hour after rSOF injection, apoA-I was shifted to later eluting fractions centered on neo-HDL (EV 32 and 33 mL), with a smaller but much greater amount relative to control in fractions 34 and 35, where LF apoA-I elutes. At 3 hours, the distribution was similar, although the intensities of the bands for LF apoA-I were lower. By 20 hours, the distribution of apoA-I returned to a profile similar to that of plasma from untreated mice. Immunoblot analysis also showed that the CERM contains apoE but no apoA-I and that neo-HDL contains apoA-I and a trace of apoE ( Figure 5C ). Thus, rSOF forms CERM, neo-HDL and LF apoA-I in vivo in a reaction that is qualitatively similar to the in vitro reaction. 7 Similarly, apoE appeared in neo-HDL at early time points after rSOF but was associated with HDL at 1200 minutes (Supplemental Figure III) .
Organ Distribution of Plasma-[ 3 H]CE
Mice were injected with [ 3 H]CE-labeled plasma aliquots with or without prior treatment with rSOF. As shown in Figure 6 , the liver was the major site for clearance of HDL-[ 3 H]CE after injection. Similarly, the liver was also the major site of [ 3 H]CE removal of rSOF-treated plasma containing CERM-[ 3 H]CE, with the uptake of radiolabel at 1 hour being Ϸ65% higher than that for control. The total radioactivity associated with the spleen, kidneys, and testes was much less than that found in liver, and differences between [ 3 H]CE uptake from control and ϩrSOF-treated plasma for these organs were small and not significant. Thus, the primary in vivo effect of the rSOF reaction is to potentiate HDL-[ 3 H]CE uptake by the liver.
Discussion
We previously proposed that each in vitro rSOF reaction product-neo-HDL, LF apoA-I, and CERM-had the potential to enhance RCT. 7 Both LF apoA-I and neo-HDL are ligands for macrophage cholesterol efflux via the ATPbinding cassette transporter A1, 10, 13, 14 and CERM-CE uptake by hepatoma cells is greater than that of HDL-CE and occurs via multiple apoE-dependent receptors. 8 However, for the SOF reaction to have its greatest therapeutic potential, it must form the same products in vivo. Our data clearly show that the rSOF reaction in mice produces all of the products formed in vitro. 7 However, the relative amounts, sizes, or both of each product were different from what was observed in vitro. At early time points, the LF apoA-I accumulation in vitro 7 and in vivo are comparable, but at later time points, the plasma apoA-I concentration is greatly diminished or absent ( Figure 4B ). As with nascent HDL and reconstituted HDL, which have sizes and compositions similar to those of neo-HDL, this could occur through fusion mediated by multiple lipoprotein-modifying activities, including lecithin-:cholesterol acyltransferase, which mediates apoA-I fusion with HDL. 15, 16 Alternatively, apoA-I could form nascent HDL via interaction with the ATP-binding cassette transporter A1 transporter on cells at multiple tissue sites, or clear renally. The disappearance of neo-HDL could follow similar pathways. Like pre-␤ HDL, which is cleared renally, 17 neo-HDL is small 9 and has pre-␤ mobility (data not shown).
The same lipoprotein-modifying activities that mediate fusion of nascent HDL 16, 18 and reconstituted HDL 19 could mediate fusion of neo-HDL with itself or with coexisting HDL giving fusion products that reenter the rSOF reaction pathway to produce additional CERM that are subsequently cleared. Another possibility is that neo-HDL is directly cleared hepatically. Injection of rSOF into WT mice produced a robust reduction in plasma total cholesterol ( Figure 1A ) that was associated with the formation of CERM that disappeared from plasma over a similar time frame (Figure 2A and 2D to 2H) . The large CERM formed at 30 minutes was replaced by a smaller CERM at 60 and 180 minutes, suggesting a preference for the clearance of large CERM. Some CERM particles are very large (200 to 400 nm at tϭ30 minutes), 7 so there was some concern that they might be too large to enter the hepatic perisinusoidal space, which contains lipoprotein receptors. However, the kinetic data ( Figure 1A and 1C ) and tissue data ( Figure 6 ) indicate clearance via interaction with lipoprotein receptors, including LDLR. Given the quantitative rSOFmediated transfer of cholesterol from HDL, its exclusive target, to CERM in vitro and the formation of CERM in vivo, 7 we attribute the in vivo decrease in plasma cholesterol to the successive conversion of HDL to CERM and its hepatic removal. The concurrent reduction of cholesterol ( Figure  1A) , disappearance of the CERM (Figure 2A and 2D to 2H) and accumulation of CERM-[ 3 H]CE in liver ( Figure 6 ) support our hypothesis that the reduction in plasma cholesterol is via hepatic CERM uptake. Remarkably, in WT mice, at 1200 minutes the cholesterol levels remained low, although the CERM had essentially cleared and HDL reappeared, although at levels still below baseline ( Figure 2D to 2H). In LDLR Ϫ/Ϫ mice where other apoE receptors 8 are still present, CERM is cleared (although to a lesser extent than in WT mice), and plasma cholesterol has returned to baseline by 1200 minutes (Figure 1C and 2C) . In apoE Ϫ/Ϫ mice, rSOF injection results in CERM formation but no clearance due to absence of apoE, and plasma cholesterol levels are not altered ( Figures 1B and 2B) .
Studies with [ 3 H]cholesterol complemented these results ( Figure 3A ). Injection of [ 3 H]cholesterol after conversion to its [ 3 H]CE gave a plasma clearance time (t 1/2 ϭ18Ϯ5 minutes) that was reduced by pretreatment with rSOF (t 1/2 ϭ 7.6Ϯ1.1 minute); this half-time is shorter than that observed for plasma cholesterol decay after rSOF injection ( Figure  1A) , likely because the [ 3 H]CERM is formed before injection, whereas (as shown in Figure 1A ) rSOF must first convert HDL to CERM. As with the clearance of plasma cholesterol, the reduction in [ 3 H]CE was more profound and faster for rSOF-treated plasma than for untreated plasma. Changes in the rates of disappearance of cholesterol, though rapid, are not unprecedented. In mice, the fractional catabolic rate of HDL-CE ether, 5.7Ϯ0.60 day Ϫ1 (t 1/2 ϭϷ4 hours), is increased to 21.7Ϯ6.4 day Ϫ1 (t 1/2 ϭϷ45 minutes) by the overexpression of phospholipid transfer protein. 20 Our in vitro studies 8 showed that in vitro CERM uptake by hepatoma cells occurs via multiple apoE-dependent lipoprotein receptors 21 : LDLR, LDLR-related protein-1, and Syndecan-1, the primary heparan sulfate proteoglycan that clears triglyceride-rich lipoproteins. 22 Thus, we reasoned that the cholesterol clearance kinetics in apoE Ϫ/Ϫ and LDLR Ϫ/Ϫ mice would provide mechanistic support to our earlier hypothesis 7 that the occurrence of apoE on a CERM would mediate increased plasma CE clearance as CERM in vivo via LDLR. In apoE Ϫ/Ϫ mice, Figure 2B clearly shows rSOFmediated CERM formation, although the maximum amount formed was less than that seen in WT (Figure 2A versus 2B) in spite of the disappearance of CERM in the WT mice. Also, the CERM formed in apoE Ϫ/Ϫ mice up to 180 minutes were smaller than those formed in WT mice. The smaller amount and initial size of CERM formed in the apoE Ϫ/Ϫ versus WT and LDL Ϫ/Ϫ mice was likely due to the lower plasma concentration of HDL, the CERM precursor, in apoE Ϫ/Ϫ mice of HDL, 23, 24 and the correlation of decreasing the HDL/rSOF ratio reducing CERM size. 7 However, at 1200 minutes, a larger and more prominent CERM peak was observed in apoE Ϫ/Ϫ mice, which may be due to CERM fusion. Despite CERM formation in the apoE Ϫ/Ϫ mice, according to Figure  1B , plasma cholesterol remained unchanged up to 1200 minutes. Given that rSOF formed CERM in apoE Ϫ/Ϫ mice but was not cleared, we conclude that apoE is required for CERM-CE clearance.
A similar kinetic analysis for rSOF-treated LDLR Ϫ/Ϫ mice revealed a greatly modulated reduction in plasma cholesterol clearance (Ϫ20% versus Ϫ43% for WT). These data were corroborated by the chromatographic profiles showing a slower reduction in CERM absorbance ( Figure 2C) , with the CERM peak absorbance at 1200 minutes after rSOF injection being more profound than that of WT. Given the CERM formation in both WT and LDL Ϫ/Ϫ mice but a slower rate of cholesterol clearance in the latter case, we conclude that the LDLR is an important but not exclusive ligand for CERM uptake. Although our in vitro hepatocyte studies showed that CERM-CE uptake is mediated by multiple apoE-dependent receptors as well as scavenger receptor class B type 1, 8 our in vivo data suggest that most hepatic CERM-CE uptake occurs via the LDLR and that the final near-total clearance at tϭ1200 minutes occurs more slowly via other receptors.
The liver was the major site for clearance of both control and rSOF-treated HDL-[ 3 H]CE, with liver uptake being Ϸ65% higher and with rSOF treatment ( Figure 6 ) accounting for Ͼ99% plasma cholesterol removal. Uptake by other organs was small and not significantly affected by rSOF treatment. Thus, the primary in vivo effect of the rSOF reaction is to potentiate the transfer of HDL-[ 3 H]CE to the liver. Dosing tests revealed rSOF in vivo potency; an ED 1/2 ϭ 0.18 g/mouse ( Figure 3B ) corresponds to a concentration of 2 pmol/L, and size exclusion chromatography revealed rSOF activity at a dose of 1 ng/mouseϭϷ10 fmol/L ( Figure 4A ). These respective doses correspond to Ϸ0.5 mg and 3 g for a 75-kg human. Given that the LDLR mediates a major component of hepatic CERM removal, it may be possible to boost rSOF potency with statins, which increase the number of hepatic LDLR.
Could the rSOF Reaction be Used Therapeutically?
Our tests add support our initial hypothesis that the rSOF reaction can be used to enhance RCT. As a virulence factor, it is reasonable to question the therapeutic value of rSOF. Although S. pyogenes causes several diseases with varying degrees of morbidity (impetigo, tonsillitis, and pharyngitis), they are usually not fatal. More importantly, there are examples of bacterial virulence determinants and toxins that are safe therapeutically. Anthrax toxins have been used to target and kill cancer cells, and the isolated toxins are not always health hazards. 25 The botulinum toxin (Botox) is used as a muscle relaxant and to treat facial wrinkles. 26 Streptokinase, a streptococcal virulence factor, is used as a thrombolytic agent. 27 Thus, although bacterial virulence factors may contribute to the pathogenesis of infections, harm from the purified virulence factors is not obligatory. Although rSOF itself may not reach human therapy, the reaction, which is a physical and not enzymatic process, might be catalyzed by rSOF analogs or even small molecules based on the mechanism that we described previously. 7 Although increasing HDL-C is thought to be cardioprotective, the relationship is not axiomatic, and there is a growing body of evidence that efficient RCT, which may or may not be associated with high HDL-C, is more important to cardioprotection than is high HDL. Macrophage cholesterol efflux to plasma better correlates with the levels of pre-␤1 HDL, presumably a preferred cholesterol acceptor, rather than total HDL. 28 In murine models of atherosclerosis, hepatic overexpression of scavenger receptor class B type 1 decreases plasma HDL-C 29 -31 ; increases HDL-CE clearance, 30 -32 biliary cholesterol, and its transport into bile 29, 31, 33 ; and reduces atherosclerosis. 34 -36 Conversely, ablated or attenuated hepatic scavenger receptor class B type 1 expression elevates plasma HDL-C, reduces selective HDL-CE clearance, 37 and is atherogenic. 37, 38 Finally, a study in humans showed that even after adjustment for HDL-C and apoA-I levels, the magnitude of macrophage cholesterol efflux capacity is inversely associated with atherosclerosis. 39 Thus, future therapies might better focus on enhancing RCT irrespective of effects on plasma HDL-C concentrations. 40 The rSOF-meditated reduction of plasma cholesterol via increased hepatic CE uptake suggests that new therapies based on this reaction may be feasible. This will ultimately be determined by tests of the effects of rSOF on RCT and atheroregression in mouse models of dyslipidemia and atherosclerosis. 
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